For the treatment of breast cancer, antibody-drug conjugates are emerging as effective players that could impact all subtypes of this disease, according to Kevin Kalinsky, MD, MS, Director of the Glen...
Younger women with breast cancer differ from their older counterparts in ways that should be appreciated by their clinicians, according to Ann H. Partridge, MD, MPH, FASCO, Vice Chair of Medical Oncol...
With three new HER2-targeted therapies approved in the past 15 months alone, the treatment landscape for patients with metastatic breast cancer has become increasingly crowded. In the third-line setti...
New data from the prospective Neoadjuvant Breast Symphony Trial (NBRST), which demonstrated the predictive and prognostic abilities of the MammaPrint and BluePrint assays and underpinned their preoper...
In updated results from the pivotal DESTINY-Breast01 trial, trastuzumab deruxtecan-nxki (T-DXd) demonstrated high rates of durable responses consistent with prior results, with encouraging progression...
Few studies documenting the benefit of neoadjuvant chemotherapy for breast cancer have been conducted in minority populations. A single-institution study reported at PER's Miami Breast Cancer Conferen...